Immuno-Oncology | Specialty

Dr. Reid on Assessing irAEs in Patients With Cancer

July 13th 2020

Pankti Reid, MD, MPH, discusses assessing immune-related adverse effects (irAEs) patients with cancer.

Novel Combos May Jumpstart the CD40 Immune-Stimulating Checkpoint

July 8th 2020

Investigators are working on a new generation of therapies that activate CD40, an immune checkpoint that helps promote an antitumor response by boosting T-cell–stimulatory signals.

Dr. Gupta on Challenges With Perioperative Immunotherapy in Bladder Cancers

July 8th 2020

Shilpa Gupta, MD, discusses challenges with perioperative immunotherapy in bladder cancer.

Yale Cancer Center Researchers Awarded $2.8 Million Cancer Systems Immunology Grant

July 7th 2020

Yale Cancer Center researchers were awarded a $2.8 million grant from the National Cancer Institute to evaluate and model cytokine signaling related to immunotherapy for cancer.

Dr. Chaft on Predictive Biomarkers in Lung Cancer

July 6th 2020

Jamie E. Chaft, MD, discusses predictive biomarkers in lung cancer.

Fakih Fleshes Out Perceptions on Pembrolizumab Approval in TMB-High Solid Tumors

June 30th 2020

Marwan G. Fakih, MD, discusses the June 2020 FDA approval of pembrolizumab for use in select patients with unresectable or metastatic solid tumors that are tumor mutational burden–high provides a potentially life-saving option to those who have exhausted all other available therapies.

FDA Approves First-Line Pembrolizumab for MSI-H/dMMR Metastatic Colorectal Cancer

June 29th 2020

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Nivolumab/Ipilimumab Combo Shows Promise in Metaplastic Breast Cancer

June 26th 2020

Sylvia Adams, MD, discusses the cohort 36 findings of the DART trial in metaplastic breast cancer and the evolution of immunotherapy, specifically in this rare breast cancer subtype.

iNEST/Atezolizumab Combo Induces Neoantigen-Specific T-Cell Responses in Advanced Solid Tumors

June 22nd 2020

The addition of the individualized neoantigen specific immunotherapy RO7198457 to atezolizumab induced neoantigen-specific T-cell responses, and was found to be well tolerated in patients with advanced solid malignancies.

Neoadjuvant Atezolizumab/Chemo Combo Improves pCR in Early TNBC

June 18th 2020

The combination of atezolizumab and nab-paclitaxel, followed by doxorubicin and cyclophosphamide, demonstrated a statistically significant and clinically meaningful improvement in pathological complete response compared with placebo plus chemotherapy as a neoadjuvant treatment for patients with early triple-negative breast cancer, regardless of PD-L1 expression.

Dr. Gupta on Neoadjuvant Versus Adjuvant Immunotherapy in Urothelial Carcinoma

June 16th 2020

Shilpa Gupta, MD, discusses the potential utility of neoadjuvant versus adjuvant immunotherapy in urothelial carcinoma.

Dr. Coveler on SEA-CD40 Combo in Metastatic Pancreatic Ductal Adenocarcinoma

June 16th 2020

Andrew Coveler, MD, discusses the investigational CD40-directed monoclonal antibody SEA-CD40 in combination with gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

June 10th 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology

June 8th 2020

Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.

Dr. Lilenbaum on Future Directions With Immunotherapy in Lung Cancer

June 7th 2020

Rogerio C. Lilenbaum, MD, discusses the promising future direction of immunotherapy in patients with advanced lung cancer.

MIBC Trial Pairs 2 Immunotherapy Agents

June 5th 2020

Investigators are testing whether the addition of inhibitors targeting the PD-1 and IDO immune pathways to standard chemotherapy in the neoadjuvant setting will offer superior outcomes for patients with muscle-invasive bladder cancer.

Drakaki Describes Efforts to Leverage Immunotherapy in Urothelial Carcinoma

June 4th 2020

Alexandra Drakaki, MD, discusses the ongoing research efforts being made in urothelial cancer, unmet needs and challenges faced in the space, and work that is generating further interest in the field.

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

June 4th 2020

Jüergen Wolf, MD, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer.

MGD013 Demonstrates Encouraging Activity Across Tumor Types

June 1st 2020

MGD013, an investigational DART protein targeting PD-1 and LAG-3, demonstrated encouraging monotherapy activity as well as in combination with margetuximab in multiple tumor types.

Dr. Bazhenova on Ongoing Clinical Trials With Immunotherapy in NSCLC

May 28th 2020

Lyudmila A. Bazhenova, MD, discusses ongoing clinical trials in non–small cell lung cancer that are investigating the utility of immunotherapy.